Differential diagnosis of chronic dysimmune demyelinating polyneuropathies with and without anti-MAG antibodies

Muscle and Nerve

Volumn 31, Issue 1, 2005, Pages 52-58

  Isoardo, G ^a   Migliaretti, G ^b   Ciaramitaro, P ^c   Rota, E ^b   Poglio, F ^b   Tavella, A ^b   Paolasso, I ^b   Cavallo, F ^b   Bergamasco, B ^b,d   Cocito, D ^b,d  

^a Ospedale Civile   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c CTO HOSPITAL   (Italy)

^d IRCCS   (Italy)

Author keywords

Chronic inflammatory demyelinating polyneuropathy; Myelin associated glycoprotein (MAG); Nerve conduction studies; Paraproteinemia; Terminal latency index

Indexed keywords

IMMUNOGLOBULIN M; MYELIN ASSOCIATED GLYCOPROTEIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CHRONIC DYSIMMUNE DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMYELINATING DISEASE; DIFFERENTIAL DIAGNOSIS; ELECTROPHYSIOLOGY; FEMALE; HUMAN; IMMUNOASSAY; LATENT PERIOD; MALE; PARAPROTEINEMIA; PHENOTYPE; POLYNEUROPATHY; PRIORITY JOURNAL; ULNAR NERVE;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; BIOLOGICAL MARKERS; DIABETES COMPLICATIONS; DIAGNOSIS, DIFFERENTIAL; ELECTROMYOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELIN-ASSOCIATED GLYCOPROTEIN; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

EID: 19944427913     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/mus.20230     Document Type: Article

References (27)

1. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991;41:617-618.
2. Attarian S, Azulay JP, Boucrault J, Escande N, Pouget J. Terminal latency index and modified F ratio in distinction of chronic demyelinating polyneuropathies. Clin Neurophysiol 2001;112:457-463.
3. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989;46:878-884.
4. Busby M, Donaghy M. Chronic dysimmune neuropathy. A subclassification based upon the clinical features of 102 patients. J Neurol 2003;250:714-724.
5. Capasso M, Torrieri F, Di Muzio A, De Angelis MV, Lugaresi A, Uncini A. Can electrophysiology differentiate polyneuropathy with anti-MAG/SGPG antibodies from chronic inflammatory demyelinating polyneuropathy? Clin Neurophysiol 2002;113:346-353.
6. Cocito D, Isoardo G, Ciaramitaro P, Migliaretti G, Pipieri A, Barbero P, et al. Terminal latency index in polyneuropathy with IgM paraproteinemia and anti-MAG antibody. Muscle Nerve 2001;24:1278-1282.
7. Dimopoulos MA, Panayiotidis P, Moulopulos M, Stikakis P, Dalakas M. Waldenström macroglobulinemia: clinical features, complications and management. J Clin Oncol 2000;18:214-226.
8. Ellie E, Vital A, Steck A, Boiron JM, Vital C, Julien J. Neuropathy associated with "benign" anti-myelin associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological, pathological findings and response to treatment in 33 cases. J Neurol 1996;243:34-43.
9. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy. Neurology 1997;48:321-328.
10. Haq RU, Pendlebury WW, Fries TJ, Tandan R. Chronic inflammatory demyelinating polyradiculoneuropathy in diabetic patients. Muscle Nerve 2003;27:465-470.
11. Hattori N, Misu K, Koike H, Ichimura M, Nagamatsu M, Hirayama M, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2001;184:57-63.
12. Kaku DA, England JD, Sumner AJ. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-aissociated glycoprotein and sulphated glucuronyl paragloboside. Brain 1994;17:941-947.
13. Katz JS, Saperstein DS, Gronseth G, Amato AA, Barhon RJ. Distal acquired demyelinating symmetric neuropathy. Neurology 2000;54:615-620.
14. Martina ISJ, van Koningsvard R, Smitz PIM, van der Mechè FGA, van Doorn A, for the European Inflammatory Neuropathy Cause and Treatment (INCAT) group. Measuring vibration threshold with a graduated tuning fork in normal aging and patients with polyneuropathy. J Neurol Neurosurg Psychiatry 1998;65:743-747.
15. Maisonobe T, Chassande B, Verin M, Jouni M, Leger JM, Bouche P. Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients. J Neurol Neurosurg Psychiatry 1996;61:39-42.
16. Mygland A, Monstad P. Chronic acquired demyelinating symmetric polyneurpathy classified by pattern of weakness. Arch Neurol 2003;60:260-264.
17. Nobile-Orazio E, Francomano E, Daverio R, Barbieri S, Marmiroli P, Manfredini E, et al. Anti-myelin-associated glycoprotein IgM antibody titers in neuropathy associated with macroglobulinemia. Ann Neurol 1989;26:543-550.
18. Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000;123:710-717.
19. Notermans NC, Franssen H, Eurelings M, Van der Graaf Y, Wokke JHJ. Diagnostic criteria for demyelinating polyneuropathy associated with monoclonal gammopathy. Muscle Nerve 2000;23:73-79.
20. Radziwill AJ, Steck AJ, Renaud S, Fuhr P. Distal motor latency and residual latency as sensitive markers of anti-MAG neuropathy. J Neurol 2003;250:962-966.
21. Rotta FT, Sussman AT, Bradley WG, Ayyar DR, Shrama KR, Shebert RT. The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2000;173:129-139.
22. Saperstein DS, Katz JS, Amato AA, Barhon RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001;24:311-324.
23. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Comparison of patients without and with monoclonal gammopathy. Neurology 1993;43:2202-2209.
24. Smith IS. The natural history of chronic demyelinating neuropathy associated with benign IgM paraproteinemia. Brain 1994;117:949-957.
25. Tagawa Y, Yuki N, Hirata K. Anti-SGPG antibody in CIDP: nosological position of IgM anti-MAG/SGPG antibody-associated neuropathy. Muscle Nerve 2000;23:895-899.
26. Trojaborg W, Hays AP, Van Den Berg L, Younger DS, Latov N. Motor conduction parameters in neuropathies associated with anti-MAG antibodies and other types of demyelinating and axonal neuropathies. Muscle Nerve 1995;18:730-735.
27. van Dijk GW, Notermans NC, Franssen H, Wokke JH. Development of weakness in patients with chronic inflammatory demyelinating polyneuropathy and only sensory symptoms at presentation. A long-term follow-up study. J Neurol 1999;246:1134-1139.